Skip to content
Subscriber Only

Drugmakers Dodge a Senate Bullet, Find Some Sympathy on Pricing

  • Senate proceeding is the starting gun in a likely long process
  • Drugmaker shares rise as executives sidestep a public scolding
Video player cover image
Sen. Grassley on Drug Pricing, Debt Ceiling, Presidential Power

A highly anticipated Senate hearing on surging drug prices that was billed as a replay of a decades-ago public reckoning for the tobacco industry produced few memorable fireworks.

Instead, what emerged was a broad recognition that the U.S. health-care system is complex, and that easy fixes are in short supply.